Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins
Authors:
- 1 September 2008
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 591 (1-3) , 124-127
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucoseMolecular Cancer Therapeutics, 2007
- When translation meets transformation: the mTOR storyOncogene, 2006
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux TransportersInternational Journal of Toxicology, 2006
- Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKBMolecular Cell, 2006
- Overcoming cisplatin resistance by mTOR inhibitor in lung cancerMolecular Cancer, 2005
- Telomerase: a potential therapeutic target for cancerExpert Opinion on Therapeutic Targets, 2005
- Upstream and downstream of mTORGenes & Development, 2004
- Overexpression of Cdk6–cyclin D3 highly sensitizes cells to physical and chemical transformationOncogene, 2003
- Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissectionGenes, Chromosomes and Cancer, 1996